Related Experiment Video
Updated: Jun 9, 2026
Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation
Published on: January 10, 2025
Superoxide Dismutase-Centered Modulation by Curcumin in Cardiovascular Diseases: Mechanistic Insights and
Danial Khayatan1,2, Seyed Mehrad Razavi1,2, Zahra Najafi Arab1,2
1Department of Toxicology & Pharmacology, TeMS.C. Islamic Azad University, Tehran, Iran.
Insights
Curcumin enhances superoxide dismutase (SOD) activity to protect the cardiovascular system from oxidative stress and inflammation. While preclinical studies show promise, further clinical research is needed to confirm these benefits in humans.
Area of Science:
- Cardiovascular research
- Redox biology
- Pharmacology
Background:
- Cardiovascular diseases (CVD) are a leading cause of death, linked to imbalanced redox homeostasis and inflammation.
- Superoxide dismutase (SOD) enzymes (SOD1, SOD2, SOD3) are crucial for managing reactive oxygen species (ROS) and maintaining cardiovascular health.
- Impaired SOD function contributes to endothelial dysfunction, heart muscle damage, and blood vessel alterations.
Purpose of the Study:
- To review the mechanistic and translational evidence linking curcumin's cardioprotective effects to SOD modulation.
- To highlight the role of SOD as a central mediator of curcumin's benefits in cardiovascular disease contexts.
- To identify gaps in clinical translation for curcumin's therapeutic potential in CVD.
Main Methods:
- Review of preclinical studies on curcumin's effects on SOD activity and expression in various CVD models.
- Analysis of signaling pathways influenced by curcumin, focusing on their convergence with SOD-mediated redox regulation.
- Examination of recent advances in nanodelivery systems for improving curcumin's bioavailability and efficacy.
- Synthesis of existing mechanistic and translational data.
Main Results:
- Curcumin consistently enhances SOD activity and expression in preclinical models, bolstering antioxidant defenses.
- Curcumin treatment attenuates oxidative damage, inflammation, apoptosis, and fibrosis in models of myocardial infarction, cardiomyopathy, hypertension, and diabetic complications.
- Curcumin's beneficial effects are increasingly attributed to its modulation of SOD-mediated redox regulation, despite influencing other pathways like NF-κB, PI3K/AKT, and Nrf2.
- Nanodelivery systems have shown potential to improve curcumin's bioavailability and in vivo efficacy.
Conclusions:
- Superoxide dismutase (SOD) is positioned as the key mediator of curcumin's cardioprotective effects.
- Curcumin demonstrates significant potential in preclinical models for treating various cardiovascular diseases by enhancing SOD function.
- There is a critical need for clinical validation to translate the promising preclinical findings of curcumin into effective human therapies for CVD.
Abstract:
Cardiovascular diseases (CVD) remain the leading global cause of morbidity and mortality, driven in part by dysregulated redox homeostasis and chronic inflammation. Superoxide dismutase (SOD), a key enzymatic defence against reactive oxygen species (ROS), plays a central role in maintaining cardiovascular integrity through regulation of oxidative stress across cytosolic (SOD1), mitochondrial (SOD2) and extracellular (SOD3) compartments. Impairment of SOD function contributes directly to endothelial dysfunction, myocardial injury and vascular remodelling. Curcumin (Cur), a pleiotropic polyphenol derived from Curcuma longa, has emerged as a potent modulator of SOD activity and expression. Evidence from preclinical models consistently demonstrates that Cur enhances SOD-dependent antioxidant defences, thereby attenuating oxidative damage, inflammation, apoptosis and fibrosis across multiple CVD contexts, including myocardial infarction, cardiomyopathy, hypertension and diabetic complications. While Cur also influences additional signalling pathways, such as NF-κB, PI3K/AKT and Nrf2, these effects are increasingly understood to converge on SOD-mediated redox regulation. Recent advances in nanodelivery systems have further improved Cur bioavailability and its capacity to modulate SOD activity in vivo. However, despite robust preclinical evidence, clinical validation remains limited. This review synthesizes current mechanistic and translational evidence, positioning SOD as the central mediator of Cur's cardioprotective effects and highlights key gaps in clinical translation.
